INVEGA TRINZA® Prolactin Data
Observed in the Double-blind Phase
% of Patients with Potentially Prolactin-related Adverse Reactions1,2*
*Prolactin adverse reaction reports among all patients in the double-blind phase, regardless of baseline prolactin levels.
†One female on INVEGA TRINZA® reported amenorrhea.
Observed in the Open-label Phase*†
% of Patients with Potentially Prolactin-related Adverse Reactions1,2‡
*Elevations of prolactin to above the reference range (>13.13 ng/mL in males and >26.72 ng/mL in females) during the open-label phase relative to baseline.
†During the open-label phase, subjects received several doses of INVEGA SUSTENNA® (paliperidone palmitate) followed by a single dose of INVEGA TRINZA®.
‡Prolactin adverse reaction reports among all patients in the open-label phase, regardless of baseline prolactin levels
References: 1. INVEGA TRINZA® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; February 2021. 2. Data on file. Janssen Pharmaceuticals, Inc., Titusville, NJ.